论文部分内容阅读
目的 探讨乳腺癌组织中GST -π的表达及可能的作用机制。方法 采用免疫组化S -P法 ,并结合增殖细胞核抗原 (PCNA)表达及临床分期 ,研究乳腺癌组织中GST -π及PCNA表达。结果 乳腺癌中GST -π表达为 63 .6% (2 8/44 ) ,临床Ⅲ期表达显著高于临床Ⅰ、Ⅱ期。PCNA在乳腺癌组织中高表达为 72 .7% ,在淋巴结转移组和非转移组之间 ,差异显著 (P <0 .0 1 ) ;GST -π与PCNA表达呈正相关。结论 PCNA的阳性率与淋巴结转移有关 ,联合GST -π检测 ,对乳腺癌化疗药物的选择及预后的判断有参考价值
Objective To investigate the expression of GST-π in breast cancer and its possible mechanism. Methods The expression of GST-π and PCNA in breast cancer tissues were studied by immunohistochemical S-P method combined with the expression of PCNA and clinical stage. Results The expression of GST-π in breast cancer was 63.6% (28/44). The expression of GST-π in stage Ⅲ was significantly higher than that in stage Ⅰ and Ⅱ. The expression of PCNA in breast cancer was 72.7%, which was significantly different between lymph node metastasis group and non-metastasis group (P <0.01). There was a positive correlation between the expression of PCNA and GST-π. Conclusions The positive rate of PCNA is related to lymph node metastasis. Combined with GST-π, it is valuable for the selection of breast cancer chemotherapy drugs and prognosis